Human immunoglobulin allotypes: Possible implications for immunogenicity

mAbs

Volumn 1, Issue 4, 2009, Pages 332-338

  Jefferis, Roy ^a   Lefranc, Marie Paule ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UMR 9002 CNRS UM   (France)

Author keywords

Anti therapeutic antibody; Antibody therapeutics; Human IgG; IgG allotypes; IgG glycosylation; Immunogenicity; Polymorphisms

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; AMINO ACID; BASILIXIMAB; CETUXIMAB; CHIMERIC ANTIBODY; DACLIZUMAB; EPITOPE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN IDIOTYPE; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; ORTHOCLONE; PALIVIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; THREONINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOIMMUNIZATION; ANTIGEN SPECIFICITY; CROHN DISEASE; ENZYME POLYMORPHISM; HAPLOTYPE; HEAVY CHAIN; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN VARIABLE REGION; LIGHT CHAIN; MULTIPLE MYELOMA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS;

EID: 70349769842     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.4.9122     Document Type: Review

References (57)

1. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24:1241-1252 (Pubitemid 44564769)
2. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol 2008; 39:113-118
3. Jenkins N. Modification of therapeutic proteins: challenges and prospects. Cytotechnology 2007; 53:121-125 (Pubitemid 46944878)
4. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009; 4:186-201
5. Jefferis R. Immunoglobulins: Allotypes. In: Roitt IM, Delves PJ, eds. Encyclopaedia of Immunology. 2nd edition. Saunders, Florida. 1998.
6. Chirino AJ, Ary ML, Marshall. SA Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 2004; 9:82-90.
7. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349-356 (Pubitemid 46696550)
8. Moutel S, Perez F. Antibodies - Europe. Engineering the next generation of antibodies. Biotechnol J 2008; 3:298-300.
9. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2008 Nov 19. [Epub ahead of print]
10. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004; 4:89-99.
11. Nezlin R, Ghetie V. Interactions of immunoglobulins outside the antigen-combining site. Adv Immunol 2004; 82:155-215. (Pubitemid 38209511)
12. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401-1413 (Pubitemid 47475656)
13. Lefranc G, Lefranc M-P. The Immunoglobulin Facts Book. London: Academic Press 2001; 1-458
14. Guidicelli V, Chaume D, Lefranc M-P. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucl Acids Res 2005; 256-261 (Pubitemid 40207873)
15. Grubb R. Agglutination of erythrocytes coated with incomplete anti-Rh by certain rheumatoid arthritic sera and some other sera; the existence of human serum groups. Acta Pathol Microbiol Scand 1956; 39:95-197.
16. Grubb R. Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 1995; 12:191-197
17. Grubb R. Allotypes: perspectives and future directions. Exp Clin Immunogenet 1995; 12:217-221
18. Oudin J, Michel M. Idiotypy of rabbit antibodies. I. Comparison of idiotypy of antibodies against Salmonella typhi with that of antibodies against other bacteria in the same rabbits, or of antibodies against Salmonella typhi in various rabbits. J Exp Med 1969; 130:595-617.
19. Natvig JB, Kunkel HG. Human immunoglobulins: classes, subclasses, genetic variants, and idiotypes. Adv Immunol 1973; 16:1-59.
20. Torres M, Casadevall A. The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol 2008; 29:91-97
21. Dam TK, Torres M, Brewer CF, Casadevall A. Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand. J Biol Chem 2008 283:31366-31370
22. Recommendations for the Nomenclature of Human Immunoglobins International Union of Immunological Sciences. Eur J Biochem 1974; 45:5-6.
23. WHO: Review of the notation for allotypic and related markers of human immunoglobulins. Eur J Immunol 1976; 6:59.
24. Ghanem N, Dariavach P, Bensmana M, Chibani J, Lefranc G, Lefranc MP. Polymorphism of immunoglobulin lambda constant region genes in populations from France, Lebanon, and Tunisia. Exp Clin Immunogenet 1988; 5:186-195 (Pubitemid 18240599)
25. Lefranc G, Lefranc M-P. Gm allotype and Gm haplotypes Allotypes. In IMGT Repertoire (IG and TR). IMGT®, the international ImMunoGeneTics information system®. http://www.imgt./textes/IMGTrepertoire/Proteins/allotypes/human/ IGH/IGHC/Hu-IGHCallotypes1.html
26. Lefranc G, Lefranc MP. Prevelent Gm haplotypes of the human IGHG3,IGHG1 and IGHG2 alleles in different populations. Allotypes. In: IMGT Repertoire (IG and TR). IMGT®, the international ImMunoGeneTics information system®.http://www.imgt.org/textes/IMGTrepertoire/Proteins/allotypes/human/ IGH/IGHC/Hu-IGHCallotypes2.html
27. Lefranc G, Loiselet J, Rivat L, Ropartz C. Gm, Km and Isf allotypes in the Lebanese population. Acta Anthropogenetica 1976; 1:34-45.
28. Dugoujon JM, Hazout S, Loirat F, Mourrieras B, Crouau-Roy B, Sanchez-Mazas A. GM haplotype diversity of 82 populations over the world suggests a centrifugal model of human migrations. Am J Phys Anthropol 2004; 125:175-192 (Pubitemid 39249783)
29. Calderón R, Lodeiro R, Varela TA, Fariña J, Ambrosio B, Guitard E, et al. GM and KM immunoglobulin allotypes in the Galician population: new insights into the peopling of the Iberian Peninsula. BMC Genet 2007; 8:37
30. Kloosterman A. Application of immunoglobulin allotyping in forensic stain analysis: reliability and sensitivity of Gm and Km typing. Exp Clin Immunogenet 1989; 6:123-132 (Pubitemid 18267875)
31. Schanfield MS. Application of immunoglobulin heavy chain (GM, AM) and light chain (KM) allotypes to cases of disputed paternity. Exp Clin Immunogenet 1989; 6:112-122
32. Lefranc G, Chaabani H, Van Loghem E, Lefranc MP, De Lange G, Helal AN. Simultaneous absence of the human IgG1, IgG2, IgG4 and IgA1 subclasses: immunological and immunogenetical considerations. Eur J Immunol 1983, 13:240-244
33. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992; 89:4285-4289
34. Hougs L, Svejgaard A, Barrington T. The first constant-domain (CH1) exon of human IGHG2 is polymorphic and in strong linkage disequilibrium with the CH2 exon polymorphism encoding the G2m(n+) allotype in Caucasians. Immunogenetics 2001;52:242-248 (Pubitemid 32142811)
35. Dard P, Lefranc MP, Osipova L, Sanchez-Mazas A. DNA sequence variability of IGHG3 alleles associated to the main G3m haplotypes in human populations. Eur J Hum Genet 2001; 9:765-772 (Pubitemid 33014589)
36. Dard P, Huck S, Frippiat JP, Lefranc G, Langaney A, Lefranc MP, et al. The IGHG3 gene shows a structural polymorphism characterized by different hinge lengths: sequence of a new 2-exon hinge gene. Hum Genet 1997; 99:138-411. (Pubitemid 26419873)
37. Lefranc G, Lefranc M-P. Km allotypes. In IMGT Repertoire (Ig and TR). IMGT®, the international ImMunoGenTics information system®. http://imgt.cines.fr/textes/IMGTrepertoire/Proteins/allotypes/human/IGK/IGKC/ Hu-IGKCallotypes.html#t1
38. Hieter PA, Hollis GF, Korsmeyer SJ, Waldmann TA, Leder P. Clustered arrangement of immunoglobulin lambda constant region genes in man. Nature 1981; 294:536-540
39. Dariavach P, Lefranc G, Lefranc MP. Human immunoglobulin C lambda 6 gene encodes the Kern+Oz-lambda chain and C lambda 4 and C lambda 5 are pseudogenes. Proc Natl Acad Sci USA 1987; 84:9074-9078
40. Niewold TA, Murphy CL, Weiss DT, Solomon A. Characterization of a light chain product of the human JC lambda 7 gene complex. J Immunol 1996; 157:4474-4477 (Pubitemid 126449367)
41. Jefferis R, Reimer CB, Skvaril F, de Lange G, Ling NR, Lowe J, et al. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol Lett 1985; 10:223-252
42. Walker MR, Solomon A, Weiss DT, Deutsch HF, Jefferis R. Immunogenic and antigenic epitopes of Ig. XXV. Monoclonal antibodies that differentiate the Mcg+/Mcg- and Oz+/Oz- C region isotypes of human lambda L chains. J Immunol 1988; 140:1600-1604
43. Lefranc G, Lefranc M-P. Isotypes: Human IGLC. In IMGT Repertoire (IG and TR). IMGT®, the international ImMunoGeneTics information system®. http://imgt.cines.fr/textes/IMGTrepertoire/Proteins/isotypes/human/IGL/IGLC/ Hu-IGLCisotypes.html
44. Jefferis R, Reimer CB, Skvaril F, de Lange GG, Goodall DM, Bentley TL, et al. Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study. Immunol Lett 1992; 31:143-168
45. Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics 2009; 19:383-387
46. Gorman SD, Clark MR. Humanisation of monoclonal antibodies for therapy. Sem Immunol 1990;2:457-466
47. Ambrosino DM, Schiffman G, Gotschlich EC, Schur PH, Rosenberg GA, DeLange GG, et al. Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J Clin Invest 1985; 75:1935-1942.
48. Granoff DM, Suarez BK, Pandey JP, Shackelford PG. Genes associated with the G2m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 1988; 157:1142-1149
49. Sarvas H, Rautonen N, Mäkelä O. Allotype-associated differences in concentrations of human IgG subclasses. J Clin Immunol 1991; 11: 39-45.
50. Oxelius VA. Immunoglobulin constant heavy G subclass chain genes in asthma and allergy. Immunol Res 2008; 40:179-191 (Pubitemid 351916613)
51. Rodriguez ME, van der Pol WL, Sanders LA, van de Winkel JG. Crucial role of FcgammaRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J Infect Dis 1999; 179:423-433
52. Dugoujon JM, Cambon-Thomsen A. Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Autoimmunity 1995;22:245-260 (Pubitemid 26198962)
53. Propert D. Immunoglobulin allotypes and RFLPs in disease association. Exp Clin Immunogenet 1995; 12:198-205.
54. Pandey JP. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 2000; 19:613-617
55. Pandey JP, Nietert PJ, Klaamas K, Kurtenkov O. A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunol Immunother. 2009 Apr 14.[Epub ahead of print]
56. Rogers KA, Scinicariello F, Attanasio R. IgG Fc receptor III homologues in non-human primate species: genec characterization and ligand interactions. J Immunol 2006; 177:3848-3856 (Pubitemid 44359919)
57. Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 2004; 111:66-74. (Pubitemid 38091051)